Literature DB >> 6798034

Isolation and partial characterization of blood group A and H active glycosphingolipids of rat small intestine.

M E Breimer, G C Hansson, K A Karlsson, H Leffler.   

Abstract

Blood group A and H active glycosphingolipids have been isolated from rat small intestine. By mass spectrometry of the permethylated and LiAlH4-reduced permethylated glycolipid derivatives, the A glycolipids were shown to contain four (A-4), six (A-6), and 12 (A-12) sugar residues, respectively. The anomeric structure of the A-4 and A-6 glycolipids was established by proton NMR spectroscopy of the permethylated-reduced derivatives. Acid degradation and gas chromatography were used for analysis of binding positions. The structures of the A-4 and A-6 glycolipids were GalNAcp alpha 1 leads to 3Galp(2 comes from 1Fucp alpha) beta 1 leads to Glcp beta 1 leads to 1Cer and GalNAcp alpha 1 leads to 3Galp(2 comes from 1Fucp alpha) beta 1 leads to 3GlcNAcp beta 1 leads to 4Galp beta 1 leads to 4Glcp beta 1 leads to 1Cer. The third glycolipid (A-12) was a branched dodecaglycosylceramide with two blood group A determinants. The complete structure of this glycolipid has not yet been solved. The blood group A activity was the same for the A-6 and A-12 glycolipids based on an equal number of blood group A determinants, but the activity of the A-4 compound was only about half of the others. The A-6 glycolipid was based on a type 1 (Gal beta 1 leads to 3GlcNAc) carbohydrate chain, thus differing from the already known isomer based on a type 2 chain (Gal beta 1 leads to 4GlcNAc) present in human erythrocyte. The blood group A activity of these two glycolipids was found to be identical. The three rat intestinal blood group A active glycolipids were exclusively located to the mucosa epithelial cells. The blood group H active tri- and pentaglycosylceramides (H-3 and H-5), presumed to be the precursors of the A-4 and A-6 glycolipids, were also identified. A 10-sugar glycolipid (H-10), a possible precursor of A-12, was not detected.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6798034

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Glycolipid- and glycoprotein-based blood group A antigen expression in human thrombocytes. A1/A2 difference.

Authors:  J Holgersson; M E Breimer; A Jacobsson; L Svensson; A Ulfvin; B E Samuelsson
Journal:  Glycoconj J       Date:  1990       Impact factor: 2.916

2.  An expanding role for apolipoprotein E in sepsis and inflammation.

Authors:  Kelley Chuang; Erica L Elford; Jill Tseng; Briana Leung; Hobart W Harris
Journal:  Am J Surg       Date:  2010-04-21       Impact factor: 2.565

3.  Blood group type glycosphingolipids of human kidneys. Structural characterization of extended globo-series compounds.

Authors:  J Holgersson; P A Jovall; B E Samuelsson; M E Breimer
Journal:  Glycoconj J       Date:  1991-10       Impact factor: 2.916

4.  Characterization of the specificity of binding of Moluccella laevis lectin to glycosphingolipids.

Authors:  S Teneberg; I Leonardsson; J Angström; S Ehrlich-Rogozinski; N Sharon
Journal:  Glycoconj J       Date:  1994-10       Impact factor: 2.916

5.  Structural complexity of non-acid glycosphingolipids in human embryonic stem cells grown under feeder-free conditions.

Authors:  Angela Barone; John Benktander; Jonas Ångström; Anders Aspegren; Petter Björquist; Susann Teneberg; Michael E Breimer
Journal:  J Biol Chem       Date:  2013-02-12       Impact factor: 5.157

6.  Redefinition of the carbohydrate binding specificity of Helicobacter pylori BabA adhesin.

Authors:  John Benktander; Jonas Ångström; Michael E Breimer; Susann Teneberg
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

7.  Galectin-4 N-Terminal Domain: Binding Preferences Toward A and B Antigens With Different Peripheral Core Presentations.

Authors:  Jon I Quintana; Sandra Delgado; Reyes Núñez-Franco; F Javier Cañada; Gonzalo Jiménez-Osés; Jesús Jiménez-Barbero; Ana Ardá
Journal:  Front Chem       Date:  2021-04-21       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.